HC Wainwright Increases Earnings Estimates for Scholar Rock

Scholar Rock Holding Corporation (NASDAQ:SRRK) – HC Wainwright lifted their FY2026 EPS estimates for shares of Scholar Rock in a report issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($3.23) per share for the year, up from their prior estimate of ($3.30). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2026 earnings at ($0.75) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($1.39) EPS, FY2029 earnings at ($0.12) EPS and FY2030 earnings at $1.00 EPS.

Several other research firms have also commented on SRRK. Wedbush reissued an “outperform” rating and set a $64.00 price objective on shares of Scholar Rock in a research note on Tuesday, September 15th. TD Cowen reiterated a “buy” rating on shares of Scholar Rock in a research note on Monday, September 14th. Barclays cut shares of Scholar Rock from an “overweight” rating to a “cautious” rating in a report on Tuesday, September 15th. Jefferies Financial Group raised their target price on Scholar Rock from $57.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Finally, BMO Capital Markets boosted their price objective on shares of Scholar Rock from $76.00 to $84.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $67.67.

Scholar Rock Trading Down 2.9%

SRRK opened at $46.60 on Thursday. The stock has a market cap of $5.68 billion, a PE ratio of -13.87 and a beta of 0.78. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The business has a 50 day moving average of $46.64 and a 200-day moving average of $48.23. Scholar Rock has a 52 week low of $29.35 and a 52 week high of $61.76.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The company had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter last year, the business earned ($0.90) earnings per share.

Institutional Investors Weigh In On Scholar Rock

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Scholar Rock during the second quarter valued at about $522,175,000. Redmile Group LLC boosted its stake in shares of Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after acquiring an additional 3,845,775 shares during the period. Jennison Associates LLC grew its position in shares of Scholar Rock by 19.5% during the first quarter. Jennison Associates LLC now owns 3,340,492 shares of the company’s stock worth $164,219,000 after purchasing an additional 545,304 shares in the last quarter. Jupiter Topco LLC purchased a new stake in shares of Scholar Rock during the second quarter worth about $123,279,000. Finally, Janus Henderson Group PLC raised its stake in Scholar Rock by 26.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,236,837 shares of the company’s stock valued at $109,891,000 after purchasing an additional 462,669 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Buying and Selling at Scholar Rock

In other news, Director Srinivas Akkaraju bought 146,970 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were bought at an average price of $41.59 per share, for a total transaction of $6,112,482.30. Following the purchase, the director owned 6,380,517 shares in the company, valued at $265,365,702.03. This represents a 2.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 10.30% of the company’s stock.

Key Scholar Rock News

Here’s some of the latest news about SRRK:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS forecast to a loss of $0.75 from $0.78 and its FY2026 forecast to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. Analyst outlook
• Positive Sentiment: Scholar Rock’s Q3 loss of $0.81 per share was narrower than the cited consensus estimate, and the company reported its first product revenue—potentially signaling early commercial progress. Q3 results
• Negative Sentiment: HC Wainwright sharply reduced EPS estimates for FY2027–FY2030: its FY2027 loss estimate increased to $2.66 from $1.95, and it moved FY2029 from projected earnings of $0.47 to a loss of $0.12. Its FY2030 profit estimate was cut to $1.00 from $1.44. These weaker longer-term expectations may weigh on the outlook despite the retained Buy rating.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.